PISETSKY MICHAEL A. sold $69K of SIBN

PISETSKY MICHAEL A. (SVP, Ops & Adm/Chief Legal Ofr) sold 3,725 shares of SI-BONE, Inc. (SIBN) at an average of $18.63 ($18.62–$18.65) across 2 trades on 2026-08-17.

Original reporting
SEC EDGAR · PISETSKY MICHAEL A.
Published Aug 18, 2026, 8:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
medium confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

Insider selling can be interpreted as bearish, but the disclosed dollar value is relatively small and lacks accompanying fundamental catalysts.

02

Market read

Traders may note the insider sale, but there is no new guidance, contract, or operational update to reprice the stock materially.

03

What to watch

No 10b5-1 plan is cited, but the article does not provide context on prior plans, tax events, or compensation timing, limiting inference.

Relevance 3/10Novelty 2/10Timing: filed 2026-08-18 after-hours; transaction dated 2026-08-17

Background

The article is an SEC Form 4 insider transaction disclosure for SI-BONE, Inc.

Company-level read

Ticker impact

$SIBNNeutralMedium confidence
Context

SI-BONE disclosed an insider open-market sale by SVP Ops and Chief Legal Officer Michael A. Pisetsky totaling about $69.4K.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 shows an officer sale (3,725 shares) at ~$18.63 with holdings still at 273,650 shares. No new company-specific operational or financial information is provided.

Market effects

No sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The sale may be for diversification or personal liquidity needs, especially since the filing provides no link to company performance.

Key entities

  • SI-BONE, Inc.

    Company whose insider transaction was reported on Form 4.

  • Michael A. Pisetsky

    SVP, Ops and Administration, and Chief Legal Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.